May 31, 2018 / 11:04 AM / a year ago

Madrigal Pharma's liver disease drug succeeds in mid-stage trial

May 31 (Reuters) - Madrigal Pharmaceuticals Inc said on Thursday a mid-stage trial testing its lead experimental treatment for a liver disease achieved the main goal of reducing liver fat.

Results from the trial, which tested the drug in patients with non-alcoholic steatohepatitis (NASH), showed a relative reduction of liver fat after 12 weeks and statistically significant results in week 36.

There are currently no FDA-approved treatments for NASH, which is characterized by a build-up of fat in the liver, inflammation and damaged liver cells. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below